collplant is a regenerative medicine company focused on 3d bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. our products are based on our rhcollagen (recombinant human collagen) that is produced with collplant’s proprietary plant based genetic engineering technology. our products address indications for diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. our flagship rhcollagen bioink product line is ideal for 3d bioprinting of tissues and organs, and our unique vergenix line of rhcollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds. collplant is a public company listed on the tel aviv stock exchange and on nasdaq (clgn).
Company profile
Ticker
CLGN
Exchange
Website
CEO
Yehiel Tal
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign ...
Former names
CollPlant Biotechnologies Ltd., CollPlant Holdings Ltd.
SEC CIK
CLGN stock data
Latest filings (excl ownership)
6-K
Collplant Biotechnologies Reports 2023 Full Year Financial Results and Provides Corporate Update
4 Apr 24
20-F
2023 FY
Annual report (foreign)
4 Apr 24
6-K
CollPlant Issues Letter to Shareholders
15 Feb 24
6-K
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants
2 Jan 24
6-K
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023
29 Nov 23
6-K
CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler
1 Nov 23
6-K
Current report (foreign)
10 Oct 23
6-K
CollPlant Biotechnologies Joins the United Nations Global Compact, The World’s Largest Corporate Sustainability Initiative
21 Sep 23
6-K
Report of Foreign Private Issuer
1 Sep 23
6-K
CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million
24 Aug 23
Latest ownership filings
SC 13G/A
Roumell Asset Management, LLC
13 Feb 24
SC 13G/A
Loewenbaum Lilian S.
25 Jan 24
144
Notice of proposed sale of securities
22 Sep 23
144
Notice of proposed sale of securities
12 Sep 23
SC 13G/A
MEITAV INVESTMENT HOUSE LTD
24 Jul 23
144
Notice of proposed sale of securities
14 Jun 23
SC 13G
Roumell Asset Management, LLC
13 Feb 23
SC 13G/A
INVESTMENT MANAGEMENT OF VIRGINIA LLC
30 Jan 23
SC 13G/A
Loewenbaum Lilian S.
25 Jan 23
SC 13G/A
MEITAV DASH INVESTMENTS LTD
11 Jan 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
12.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 5 |
Closed positions | 2 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 11.98 bn |
Total shares | 1.47 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Roumell Asset Management | 577.91 k | $4.69 bn |
Pinnacle Associates | 484.65 k | $3.95 bn |
Villere ST Denis J & Co | 292.72 k | $2.39 bn |
Brown Advisory | 73.85 k | $602.61 mm |
Zurcher Kantonalbank | 23.17 k | $187.92 mm |
BAC Bank Of America | 7.39 k | $60.29 mm |
UBS UBS Group AG - Registered Shares | 6.55 k | $53.43 mm |
PNC PNC Financial Services | 3.60 k | $29.38 mm |
FNY Investment Advisers | 1.54 k | $12.00 k |
Geneos Wealth Management | 750.00 | $6.08 mm |
News
HC Wainwright & Co. Reiterates Buy on CollPlant Biotechnologies, Maintains $11 Price Target
5 Apr 24
CollPlant Biotechnologies Q4 Adj EPS $(0.35) Misses $(0.07) Estimate, Sales $299.00K Miss $8.56M Estimate
4 Apr 24
Earnings Scheduled For April 4, 2024
4 Apr 24
CollPlant Biotechnologies Issues Letter To Shareholders
15 Feb 24
Press releases
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
4 Apr 24
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
4 Apr 24
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
26 Mar 24
CollPlant Issues Letter to Shareholders
15 Feb 24